Success Metrics

Clinical Success Rate
100.0%

Based on 12 completed trials

Completion Rate
100%(12/12)
Active Trials
0(0%)
Results Posted
67%(8 trials)

Phase Distribution

Ph phase_3
4
33%
Ph phase_2
2
17%
Ph phase_1
6
50%

Phase Distribution

6

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
6(50.0%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
4(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

12 of 12 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(12)

Detailed Status

Completed12

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (50.0%)
Phase 22 (16.7%)
Phase 34 (33.3%)

Trials by Status

completed12100%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_1

A Study of Modified mRNA Vaccines in Healthy Adults

NCT05397223
completedphase_2

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

NCT05606965
completedphase_3

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

NCT06602024
completedphase_3

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

NCT05827978
completedphase_1

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

NCT05827068
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05397223Phase 1

A Study of Modified mRNA Vaccines in Healthy Adults

Completed
NCT05606965Phase 2

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

Completed
NCT06602024Phase 3

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

Completed
NCT05827978Phase 3

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Completed
NCT05827068Phase 1

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

Completed
NCT05566639Phase 3

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Completed
NCT05868382Phase 2

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

Completed
NCT05415462Phase 3

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Completed
NCT05585632Phase 1

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

Completed
NCT05375838Phase 1

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

Completed
NCT05333289Phase 1

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

Completed
NCT04956575Phase 1

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

Completed

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12